Purpose: Osteoarthritic cartilage defects are unable to heal on their own and surgical approaches are often ineffective. Tissue engineering using transplantation of autologous chondrocytes is also limited. Human bone marrow stromal cells (hBMSCs, also known as bone marrow-derived mesenchymal stem cells), have been suggested as a source for cartilage reconstruction. However, studies using hBMSCs pre-differentiated into cartilage prior to transplantation failed to demonstrate formation of stable, hyaline-like cartilage that is resistant to hypertrophy in vivo. We previously determined that naive (untreated) hBMSCs were able to form stable, non-hypertrophic cartilage when transplanted subcutaneously in conjunction with fibrin microbeads covalently coated with hyaluronic acid (HyA-FMBs). In our current study, we are investigating the ability of hBMSC/HyA-FMB constructs to generate cartilage in an articular defect in immunocompromised rodents. Methods: FMB were manufactured by dehydrothermal crosslinking of concentrated thrombin activated fibrinogen emulsified in heated oil. The FMB were collected, rinsed in organic solvents and ethanol, and sieved for sizing. FMB were then coated by crosslinking HyA to their surfaces using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride. hBMSCs were cultured from orthopedic surgery bony waste and cryopreserved in liquid nitrogen. Prior to implantation in rodents, hBMSCs were thawed and incubated for 12 hours with protamine and iron oxide nanoparticles for cell tracking. Cells were then incubated in suspension with HyA-FMBs for attachment for 90 minutes. hBMSC/HyA-FMB constructs were transplanted subcutaneously into the backs of NSG immunocompromised mice using standard procedures. To create intra-articular damage, the knee capsule was accessed from a medial parapatellar incision. The patella was laterally dislocated, and the distal femur immobilized using a miniature positioning clamp. A microdrill with a 0.5mm burr was used to drill a 1.5mm deep osteochondral defect. The defect was filled with hBMSC/HyA-FMB using a 0.5mm microcurrette. The patella was relocated and the incision closed using skin adhesive. A similar defect is being created in immunocompromised SRG rats (Hera Biolabs). Mice were euthanized on day 3 (to evaluate construct integrity), at 8 weeks (to examine early cartilage formation), at 16 weeks (to assess formation of mature cartilage), and at 28 weeks (to evaluate cartilage stability). Cell integration was determined using non-decalcified cryohistology and Prussian blue staining of iron nanoparticles. Cartilage formation was assessed using H&E, toluidine blue, and immunohistochemistry of COL1, COL2, COL10. The human origin of the cells was determined by human mitochondria immunohistochemistry. Results: Subcutaneous transplants of hBMSC/HyA-FMB formed stable hyaline-like cartilage at 28 weeks. Post osteochondral defect surgery, mice had uniform defect sizing, and no visually appreciable alterations in activity. Repair construct integrity, as assessed by cryohistology at 3 days, showed intact FMB with adherent hBMSCs visualized by Prussian Blue staining; growth of fibrous tissue was also detected. Intra-articular defect studies using larger cohorts of rodents and longer-term time points are currently underway. Conclusions: hBMSC/HyA-FMB constructs formed stable hyaline cartilage in a subcutaneous model in vivo. These data suggest that these constructs may be a viable method for repairing osteochondral defects. Further intra-articular experimentation is underway for clinical translation of this methodology.
Read full abstract